Literature DB >> 8131820

Effect of interleukin 2 on intractable herpes virus infection and chronic eczematoid dermatitis in a patient with Wiskott-Aldrich syndrome.

H Azuma1, H Sakata, M Saijyou, A Okuno.   

Abstract

Recombinant interleukin 2 (rIL2) was administered to a patient with Wiskott-Aldrich syndrome for the treatment of an intractable facial herpetiform lesion. This treatment appeared to be effective in suppressing the virus activity. At the same time, a transient improvement of the chronic eczematoid dermatitis was observed. During rIL2 administration, the CD3+ and CD4+ subsets of peripheral blood lymphocytes increased in number. These changes might play an important role in the induction of anti-viral immunity and in the improvement of dermatitis.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8131820     DOI： 10.1007/bf01957224

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN： 0340-6199            Impact factor:   3.183


  15 in total

1.  Recombinant interleukin 2 therapy in severe combined immunodeficiency disease.

Authors:  R Pahwa; T Chatila; S Pahwa; C Paradise; N K Day; R Geha; S A Schwartz; H Slade; N Oyaizu; R A Good
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

2.  HLA-restricted lysis of herpes simplex virus-infected monocytes and macrophages mediated by CD4+ and CD8+ T lymphocytes.

Authors:  D J Torpey; M D Lindsley; C R Rinaldo
Journal:  J Immunol       Date:  1989-02-15       Impact factor: 5.422

3.  Interleukin-2 augments natural killer cell activity.

Authors:  C S Henney; K Kuribayashi; D E Kern; S Gillis
Journal:  Nature       Date:  1981-05-28       Impact factor: 49.962

4.  The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities.

Authors:  J P Siegel; M Sharon; P L Smith; W J Leonard
Journal:  Science       Date:  1987-10-02       Impact factor: 47.728

5.  Direct activation of human resting T cells by IL 2: the role of an IL 2 receptor distinct from the Tac protein.

Authors:  L T Bich-Thuy; M Dukovich; N J Peffer; A S Fauci; J H Kehrl; W C Greene
Journal:  J Immunol       Date:  1987-09-01       Impact factor: 5.422

6.  Augmentation of immunity to herpes simplex virus by in vivo administration of interleukin 2.

Authors:  B T Rouse; L S Miller; L Turtinen; R N Moore
Journal:  J Immunol       Date:  1985-02       Impact factor: 5.422

7.  Interleukin-2 immunotherapy in children.

Authors:  C H Chien; K H Hsieh
Journal:  Pediatrics       Date:  1990-12       Impact factor: 7.124

8.  The human MHC-restricted cellular response to herpes simplex virus type 1 is mediated by CD4+, CD8- T cells and is restricted to the DR region of the MHC complex.

Authors:  D S Schmid
Journal:  J Immunol       Date:  1988-05-15       Impact factor: 5.422

9.  Adhesive and degradative properties of human placental cytotrophoblast cells in vitro.

Authors:  S J Fisher; T Y Cui; L Zhang; L Hartman; K Grahl; G Y Zhang; J Tarpey; C H Damsky
Journal:  J Cell Biol       Date:  1989-08       Impact factor: 10.539

10.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Authors:  E A Grimm; A Mazumder; H Z Zhang; S A Rosenberg
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307
View more
  6 in total

Review 1.  An Update on the Use of Immunomodulators in Primary Immunodeficiencies.

Authors:  Pandiarajan Vignesh; Amit Rawat; Surjit Singh
Journal:  Clin Rev Allergy Immunol       Date:  2017-04       Impact factor: 8.667

2.  IL-2 induces a WAVE2-dependent pathway for actin reorganization that enables WASp-independent human NK cell function.

Authors:  Jordan S Orange; Sumita Roy-Ghanta; Emily M Mace; Saumya Maru; Gregory D Rak; Keri B Sanborn; Anders Fasth; Rushani Saltzman; Allison Paisley; Linda Monaco-Shawver; Pinaki P Banerjee; Rahul Pandey
Journal:  J Clin Invest       Date:  2011-03-07       Impact factor: 14.808

3.  Autoimmunity in wiskott-Aldrich syndrome: an unsolved enigma.

Authors:  Marco Catucci; Maria Carmina Castiello; Francesca Pala; Marita Bosticardo; Anna Villa
Journal:  Front Immunol       Date:  2012-07-18       Impact factor: 7.561

Review 4.  Primary Immunodeficiency Diseases: Current and Emerging Therapeutics.

Authors:  Beatriz E Marciano; Steven M Holland
Journal:  Front Immunol       Date:  2017-08-09       Impact factor: 7.561

Review 5.  Use of cytokine therapy in primary immunodeficiency.

Authors:  Sumita Roy-Ghanta; Jordan S Orange
Journal:  Clin Rev Allergy Immunol       Date:  2010-02       Impact factor: 10.817

Review 6.  Recurrent and Sustained Viral Infections in Primary Immunodeficiencies.

Authors:  Melanie A Ruffner; Kathleen E Sullivan; Sarah E Henrickson
Journal:  Front Immunol       Date:  2017-06-19       Impact factor: 7.561
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.